President Trump is set to sign an executive order reclassifying marijuana as a Schedule III drug, a move that has sent marijuana stocks soaring. The reclassification would mark a major shift in federal policy on marijuana, potentially opening up new opportunities for research and investment in the cannabis industry.

This decision comes after years of debate and controversy surrounding the legalization of marijuana at the state level. Currently, marijuana is classified as a Schedule I drug, which is the most restrictive category reserved for substances that are considered to have a high potential for abuse and no accepted medical use.

By reclassifying marijuana as a Schedule III drug, the Trump administration is acknowledging the growing body of evidence supporting the medical benefits of cannabis. This move is expected to have far-reaching implications for the cannabis industry, with analysts predicting a surge in investment and growth for marijuana companies.

While supporters of the reclassification argue that it will lead to increased access to medical marijuana for patients in need, critics worry about the potential for abuse and misuse. As President Trump prepares to sign the executive order, the nation waits to see how this decision will impact the future of marijuana policy in the United States.